Abstract
Abstract: :
Purpose: To compare a ocular cromoglicic acid (Intal Ophthalmic Solution 2%; Fisons, England), with ocular antihistamine, levocabastine hydrochloride (Livostin Ophthalmic Suspension 0.05%; Janssen, Belgium), in the treatment of allergic conjunctivitis using symptoms and signs scale. Methods:A total of 23 subjects with a history of allergic conjunctivitis and a positive response to a diagnostic test were valuable for safety analysis, and 23 subjects were valuable for the efficacy analysis. We performed a prospective, contralateral eye study comparing cromoglicic acid 2% in one eye with levocabastine 0.025% in the contralateral eye. Efficacy was determined 1 week after administration of study medications. Symptoms (Ocular itching, discharge, redness, lacrimation and nasal discharge) and signs score (conjunctival injection, edema, papilla, eyelid swelling and corneal change) were recorded before and 1 week after eye drop treatment. Results:Twelve patients (52.2%) selected levocabastine, 3 patients (13.0%) selected Cromoglicic acid and 8 patients evaluated to be even. Levocabastine 0.025% was statistically significantly effective more than cromoglicic acid 2% in reducing ocular itching (p=0.007) and papilla formation (p=0.02). Cromoglicic acid 2% and levocabastine 0.025% were statistically equivalent in reducing other symptoms and signs scores. Conclusion:Levocabastine 0.025% is significantly favorable and effective more than cromoglicic acid 2% in reducing ocular itching associated with allergic conjunctivitis. The two compounds are equivalent in controlling the other symptoms associated with allergic conjunctivitis.
Keywords: 366 conjunctivitis • 357 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • 436 injection